Liraglutide's Cognitive Effects in Type 2 Diabetes Patients Under Investigation in New Trial

Patients with Type 2 Diabetes Mellitus (T2DM) face a 1.5 to 2.5 times higher risk of developing Alzheimer's Disease (AD) and experience significant cognitive impairment, severely impacting quality of life. Current prevention and treatment strategies for cognitive decline in T2DM are underexplored. Glucagon-like peptide-1 (GLP-1) analogues, like Liraglutide, are known for their metabolic benefits, including enhancing glucose-dependent insulin secretion and reducing food intake. Preclinical studies have shown Liraglutide can improve insulin resistance and cognitive function in AD animal models, suggesting a potential neuroprotective role in T2DM patients.

This open, prospective, positive controlled, and randomized study aims to enroll 150 patients with Type 2 Diabetes Mellitus. Participants will receive Liraglutide as an additional treatment, though the specific dose and frequency are not detailed in the abstract. The primary endpoints include changes in cognitive function, assessed via standard cognitive tests, and various metabolic parameters. Researchers will measure BMI, waist circumference, hip circumference, waist-to-hip ratio, fasting plasma glucose, glycosylated hemoglobin, and blood lipids to comprehensively evaluate Liraglutide's effects. The study is designed to confirm the potential of Liraglutide to interfere with the occurrence and development of cognitive dysfunction in this patient population.

As this is a recruiting study (NCT05553093) with an estimated completion date of October 2027, specific findings regarding Liraglutide's effects on cognitive function in Type 2 Diabetes Mellitus patients are not yet available. The study is designed to measure changes in cognitive function, assessed via standard tests, alongside key metabolic markers. Researchers hypothesize that Liraglutide may positively impact cognitive function, building on preclinical evidence showing improved insulin resistance and cognitive function in Alzheimer's Disease animal models. The trial's overall goal is to confirm these potential benefits in a human T2DM population.

The study's primary objective is to explore the effects of Liraglutide on cognitive function in patients with Type 2 Diabetes Mellitus to make further contributions to improving patient cognitive outcomes. Secondary outcomes include monitoring changes in BMI, waist circumference, hip circumference, and waist-to-hip ratio, providing a comprehensive metabolic profile. The investigators anticipate that the results will shed light on Liraglutide's neuroprotective potential in this vulnerable patient group, particularly concerning the link between T2DM and cognitive decline.